Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

Company Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Key Stats

• Today's Range: $19.00 to $19.00
• 50-Day Range: $18.20 to $19.00
• 52-Week Range: $8.82 to $21.86
• Volume: N/A
• Average Volume: 1.36 million shs
• Market Capitalization: $794.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Intercept Pharmaceuticals Stock Analysis - MarketRank™

Intercept Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat, and ranked 917th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Intercept Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.04) to $1.93 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intercept Pharmaceuticals has a P/B Ratio of 11.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ICPT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intercept Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Intercept Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.13

Short Interest

There is no current short interest data available for ICPT.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.30

News Coverage This Week

MarketBeat has tracked 3 news articles for Intercept Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.

Percentage Held by Institutions

83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ICPT Stock Analysis - Frequently Asked Questions

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. Intercept Pharmaceuticals's revenue for the quarter was up 16.6% on a year-over-year basis.
Read the conference call transcript.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Sarepta Therapeutics (SRPT), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 8/02/2023
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ICPT
• CIK: 1270073
• Web: www.interceptpharma.com
• Phone: (646) 747-1000
• Fax: 646-747-1001
• Employees: 341
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $221.82 million
• Net Margins: -19.39%
• Pretax Margin: -18.09%
• Return on Equity: -77.48%
• Return on Assets: -11.99%

Debt

• Debt-to-Equity Ratio: 3.12
• Current Ratio: 4.22
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: $285.71 million
• Price / Sales: 2.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.72 per share
• Price / Book: 11.05

Miscellaneous

• Outstanding Shares: 41,830,000
• Free Float: 39,192,000
• Market Cap: $794.77 million
• Optionable: Optionable
• Beta: 0.88